NJ Bio, Inc.

NJ Bio is a premier contract research, development, and manufacturing organisation (CRDMO) specialising in antibody-drug conjugates (ADCs) and other bioconjugates.

Founded in Princeton, New Jersey, NJ Bio is dedicated to providing cutting-edge solutions across the antibody-drug conjugate (ADC) value chain. The company is recognised for its expertise in bioconjugation, small molecule synthesis, and linker-payload technologies. With a strong focus on innovation, NJ Bio has supported over 150 clients globally, delivering more than 500 projects since its inception. The company has earned accolades such as the prestigious World ADC Awards for its excellence in the field. Under the leadership of Dr Naresh Jain, a renowned figure in ADC development, NJ Bio continues to be a trusted partner in advancing targeted therapies.

Key Products and Services:

• Antibody-Drug Conjugates (ADCs): Comprehensive support for ADC development, including conjugation, payload-linker synthesis, and characterisation.
• Bioconjugation Services: Expertise in the development of bioconjugates, including antibody and protein conjugates for therapeutic and diagnostic purposes.
• Custom Synthesis: High-quality synthesis of small molecules, linkers, and payloads tailored to client specifications.
• Process Development and Scale-up: End-to-end support for manufacturing processes to ensure seamless scalability.
• Analytical and Quality Control: Advanced analytical capabilities for detailed characterisation and quality assurance.

NJ Bio stands out as a leader in the ADC/XDC field, combining technical innovation with a commitment to client success. With a proven track record, industry recognition, and a mission to drive transformative therapies, the company plays a pivotal role in shaping the future of targeted drug development.